CRANBURY, N.J., Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast | |
Q1 Fiscal Year 2025 Results Press Release | 11/14/2024 at 7:30 a.m. ET |
Q1 Fiscal Year 2025 Conference Call-Live | 11/14/2024 at 11:00 a.m. ET |
US Toll Free Dial-In Number: | 1-888-506-0062 |
International Dial-In Number: | 1-973-528-0011 |
Participant Access Code: | 176159 |
Q1 Fiscal Year 2025 Conference Call-Replay | 11/14/2024-11/28/2024 |
US Toll Free Dial-In Number: | 1-877-481-4010 |
International Dial-In Number: | 1-919-882-2331 |
Participant Access Code: | 51641 |
The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
| Last Trade: | US$1.10 |
| Daily Change: | -0.01 -0.90 |
| Daily Volume: | 258,981 |
| Market Cap: | US$25.810M |
December 19, 2024 December 16, 2024 November 25, 2024 November 14, 2024 November 04, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
